We are often amazed when someone is diagnosed with T1DM when there is no family history. That is because the disease is about 15 times more common in siblings of a patient with diabetes than in the general population. In addition, siblings have an average risk of 6% of developing …

I have a patient who has type 2 diabetes. He was started on long-acting insulin 8 months ago. Before adding the insulin, he was taking a daily GLP-1. He had experienced diabetic ketoacidosis (DKA) while on a SGLT-2, and did not tolerate metformin due to GI side effects. Therefore, these …

Rachele Berria MD, PhD is Vice President and Head, Diabetes Medical Unit at Sanofi, Bridgewater, New Jersey. She has a medical degree (undergrad/graduate combined program) and Obstetrics and Gynecology Board Certification from the University of Cagliari School of Medicine, Italy. Her many other educational accomplishments include a Master of Science in Clinical Investigation from the University of Texas Health Science Center at San Antonio, Texas; Ph.D. Degree in Medical Pathophysiology and Pharmacology from the University of Pisa School of Medicine, Italy; a Fellowship in Diabetes and Metabolism from the Internal Medicine Department, University of Texas Health Science Center at San Antonio, Texas;  and a Master Practitioner Certification in Effective Communication from the Neurolinguistic Programming Center of New York City, NY.

 In this week’s Homerun Slides, the breakdown of the different CGM categories. To download the complete set in PowerPoint format, just use this link: New CGM Categories and Technologies Part 2. Catch up on past Homerun Slides for New CGM Categories and Technologies: New CGM Categories and Technologies Part 1.

Genetic predisposition is an important component of the multifactorial pathogenesis of T1DM. Although often diagnosed in individuals with no known family history of T1DM, the disease is about 15 times more common in siblings of a patient than in the general population. Siblings have an average risk of 6%, although individual risk varies significantly in relation to the extent of sharing predisposing genes with the proband, which allele variants are shared, and other factors. The risk to the offspring of affected mothers and fathers is about 2–3% and 6–7%, respectively. Among twins, the observed disease concordance rates are approximately 8–10% in dizygotic twins and, with extended follow-up, more than 60% in monozygotic twins.

In this Exclusive Interview transcript, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins, and what Sanofi has in the pipeline.

In this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins.

In part 1 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the various trials of interest presented at the conference, such as the latest regarding the study of two basal insulins.

In part 2 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the products in the works at Sanofi.

In part 3, the conclusion of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the focus on the impact of certain medications on specific populations.